

The U.S. Drug Enforcement Administration issued an order temporarily placing 4-(2-chlorophenyl)-2-ethyl-9-methyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine (commonly known as etizolam), 8-chloro-6-(2-fluorophenyl)-1-methyl-4*H*-benzo[*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine (commonly known as flualprazolam), 6-(2-chlorophenyl)-1-methyl-8-nitro-4*H*-benzo[*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine (commonly known as clonazolam), 8-bromo-6-(2-fluorophenyl)-1-methyl-4*H*-benzo[*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine (alternate chemical name: 8-bromo-6-(2-fluorophenyl)-1-methyl-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepine and commonly known as flubromazolam), and 7-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2*H*-benzo[*e*][1,4]diazepin-2-one (commonly known as diclazepam), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This order was published in the *Federal Register*, Volume 88, Number 142, pages 48112-48118, and was effective July 26, 2023.

This scheduling action was taken pursuant to the following:

1. Etizolam, flualprazolam, clonazolam, flubromazolam, and diclazepam have high potential for abuse;
2. There is currently no accepted medical use in treatment in the United States;
3. There is a lack of accepted safety for use under medical supervision; and
4. Control of etizolam, flualprazolam, clonazolam, flubromazolam, and diclazepam is necessary to avoid an imminent hazard to public safety.

The U.S. Drug Enforcement Administration (DEA) issued a final rule amending the definition of “anabolic steroid” and adding new specific substances to the list of schedule III anabolic steroids. This order was published in the *Federal Register*, Volume 88, Number 146, pages 50036-50041, and was effective August 1, 2023. This action was taken to implement requirements under the Designer Anabolic Steroid Control Act of 2014 (DASCA). The DEA published this rule to amend and reorganize its regulations and to codify the statutory amendments to the Controlled Substances Act (CSA) made by DASCA. The Department is adopting these changes to maintain consistency with the format and substance of DEA regulations.

The U.S. Drug Enforcement Administration issued a final rule permanently placing *N,N*-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)ethan-1-amine (metonitazene), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, in schedule I of the Controlled Substances Act. This final rule was published in the *Federal Register*, Volume 88, Number 159, pages 56466-56469, and is effective September 18, 2023.

This scheduling action was taken pursuant to the following:

1. In order to meet the United States' obligations under the 1961 United Nations Single Convention on Narcotic Drugs;
2. Metonitazene has no currently accepted medical use in treatment in the United States;
3. Metonitazene has a pharmacological profile similar to etonitazene (schedule I), isotonitazene (schedule I), and other schedule I and II synthetic opioids; and
4. The use of metonitazene presents a high risk of abuse.

Pursuant to Section 481.034(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Health and Safety Code, Chapter 481, at least thirty-one days have expired since notice of the above referenced actions were published in the Federal Register. In the capacity as Commissioner of the Texas Department of State Health Services, Jennifer Shuford, M.D., does hereby order that the substances etizolam, flualprazolam, clonazolam, flubromazolam, and diclazepam be placed into schedule I temporarily controlled substances, amendments to schedule III anabolic steroids and hormones, and metonitazene be placed into Schedule I.

### **-Schedule I opiates**

The following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, if the existence of these isomers, esters, ethers, and salts are possible within the specific chemical designation:

- (1) Acetyl- $\alpha$ -methylfentanyl (*N*-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-*N*-phenylacetamide);
- (2) Acetylmethadol;

- (3) Acetyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylacetamide);
- (4) Acryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylacrylamide) (Other name: acryloylfentanyl);
- (5) AH-7921 (3,4-dichloro-*N*-[1-(dimethylamino) cyclohexymethyl]benzamide);
- (6) Allylprodine;
- (7) Alphacetylmethadol (except levo- $\alpha$ -cetylmethadol, levo- $\alpha$ -acetylmethadol, levomethadyl acetate, or LAAM);
- (8)  $\alpha$ -Methylfentanyl or any other derivative of fentanyl;
- (9)  $\alpha$ -Methylthiofentanyl (*N*-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl] *N*-phenylpropanamide);
- (10) Benzethidine;
- (11)  $\beta$ -Hydroxyfentanyl (*N*-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-*N*-phenylpropanamide);
- (12)  $\beta$ -Hydroxy-3-methylfentanyl (*N*-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-*N*-phenylpropanamide);
- (13)  $\beta$ -hydroxythiofentanyl (Other names: *N*-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-*N*-phenylpropionamide; *N*-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-*N*-phenylpropanamide);
- (14)  $\beta$ -Methyl fentanyl (*N*-phenyl-*N*-(1-(2-phenylpropyl)piperidin-4-yl)propionamide);
- (15)  $\beta'$ -Phenyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*,3-diphenylpropanamide) (Other name: 3-phenylpropanoyl fentanyl);
- (16) Betaprodine;
- (17) Brorphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one);
- (18) Butyryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylbutanamide);
- (19) Clonitazene;
- (20) Crotonyl fentanyl (Other name: (6-2-5) (E)-*N*-(1-Phenethylpiperidin-4-yl)-*N*-phenylbut-2-enamide);
- (21) Cyclopentyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-Phenylcyclopentanecarboxamide);
- (22) Cyclopropyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylcyclopropanecarboxamide);
- (23) Diampromide;
- (24) Diethylthiambutene;
- (25) Difenoxyin;
- (26) Dimenoxadol;
- (27) Dimethylthiambutene;
- (28) Dioxaphetyl butyrate;
- (29) Dipipanone;
- (30) Ethylmethylthiambutene;
- (31) Etonitazene;

- (32) Etoxidine;
- (33) Fentanyl carbamate (ethyl (1-phenethylpiperidin-4-yl)(phenyl)carbamate);
- (34) 4-Fluoroisobutyryl fentanyl (*N*-(4-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide) (Other name: *p*-fluoroisobutyryl fentanyl);
- (35) 2'-Fluoro *o*-fluorofentanyl (*N*-(1-(2-fluorophenethyl)piperidin-4-yl)-*N*-(2-fluorophenyl)propionamide (Other name: 2'-fluoro 2-fluorofentanyl);
- (36) Furanyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylfuran-2-carboxamide);
- (37) Furethidine;
- (38) Hydroxypethidine;
- (39) Isobutyryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylisobutyramide);
- (40) Isotonitazene (*N,N*-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)ethan-1-amine);
- (41) Ketobemidone;
- (42) Levophenacylmorphane;
- (43) Meprodine;
- (44) Methadol;
- (45) Methoxyacetyl fentanyl (2-methoxy-*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylacetamide);
- (46) 4'-Methyl acetyl fentanyl (*N*-(1-(4-methylphenethyl)piperidin-4-yl)-*N*-phenylacetamide);
- (47) 3-Methylfentanyl (*N*-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-*N*-phenylpropanamide);
- (48) 3-Methylthiofentanyl (*N*-[3-methyl-1-(2-thienyl)ethyl-4-piperidiny]-*N*-phenylpropanamide);
- \*(49) Metonitazene (*N,N*-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)ethan-1-amine);
- (50) Moramide;
- (51) Morpheridine;
- (52) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- (53) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);
- (54) Noracymethadol;
- (55) Norlevorphanol;
- (56) Normethadone;
- (57) Norpipanone;
- (58) Ocfentanil (*N*-(2-fluorophenyl)-2-methoxy-*N*-(1-phenethylpiperidin-4-yl)acetamide);
- (59) *o*-Fluoroacryl fentanyl (*N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)acrylamide);
- (60) *o*-Fluorobutyryl fentanyl (*N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)butyramide (Other name: 2-fluorobutyryl fentanyl);

- (61) *o*-Fluorofentanyl (*N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)propionamide) (Other name: 2-fluorofentanyl);
- (62) *o*-Fluoroisobutyryl fentanyl (*N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide);
- (63) *o*-Methyl acetylfentanyl (*N*-(2-methylphenyl)-*N*-(1-phenethylpiperidin-4-yl)acetamide (Other name: 2-methyl acetylfentanyl);
- (64) *o*-Methyl methoxyacetyl fentanyl (2-methoxy-*N*-(2-methylphenyl)-*N*-(1-phenethylpiperidin-4-yl)acetamide (Other name: 2-methyl methoxyacetyl fentanyl);
- (65) *p*-Chloroisobutyryl fentanyl (*N*-(4-chlorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide);
- (66) *p*-Fluorobutyryl fentanyl (*N*-(4-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)butyramide);
- (67) *p*-Fluorofentanyl (*N*-(4-fluorophenyl)-*N*-[1-(2-phenethyl)-4 piperidinyl]propanamide);
- (68) *p*-Fluoro furanyl fentanyl (*N*-(4-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
- (69) *p*-Methoxybutyryl fentanyl (*N*-(4-methoxyphenyl)-*N*-(1-phenethylpiperidin-4-yl)butyramide);
- (70) *p*-Methylfentanyl (*N*-(4-methylphenyl)-*N*-(1-phenethylpiperidin-4-yl)propionamide (Other name: 4-methylfentanyl);
- (71) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- (72) Phenadoxone;
- (73) Phenampromide;
- (74) Phencyclidine;
- (75) Phenomorphan;
- (76) Phenoperidine;
- (77) Phenyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylbenzamide (Other name: benzoyl fentanyl);
- (78) Piritramide;
- (79) Proheptazine;
- (80) Properidine;
- (81) Propiram;
- (82) Tetrahydrofuranyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenyltetrahydrofuran-2-carboxamide);
- (83) Thiofentanyl (*N*-phenyl-*N*-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide);
- (84) Thiofuranyl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylthiophene-2-carboxamide (Other names: 2-thiofuranyl fentanyl; thiophene fentanyl);
- (85) Tilidine;
- (86) Trimeperidine;
- (87) U-47700 (3,4-dichloro-*N*-[2-(dimethylamino)cyclohexyl]-*N*-methylbenzamide);
- (88) Valeryl fentanyl (*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylpentanamide); and,

(89) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol).

**-Schedule I temporarily listed substances subject to emergency scheduling by the U.S. Drug Enforcement Administration.**

Unless specifically excepted or unless listed in another schedule, a material, compound, mixture, or preparation that contains any quantity of the following substances or that contains any of the substance's isomers, esters, ethers, salts and salts of isomers, esters, and ethers if the existence of the salts, esters, ethers isomers, and salts of isomers, esters, ethers is possible within the specific chemical designation:

(1) Fentanyl-related substances.

(1-1) Fentanyl-related substance means any substance not otherwise listed under another Administration Controlled Substance Code Number, and for which no exemption or approval is in effect under Section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that is structurally related to fentanyl by one or more of the following modifications:

(1-1-1) Replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle,

(1-1-2) Substitution in or on the phenethyl group with alkyl, alkenyl, alkoxy, hydroxyl, halo, haloalkyl, amino or nitro groups,

(1-1-3) Substitution in or on the piperidine ring with alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups,

(1-1-4) Replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle, and/or

(1-1-5) Replacement of the *N*-propionyl group by another acyl group.

(1-2) This definition includes, but is not limited to, the following substances:

(1-2-1) *N*-(1-(2-Fluorophenethyl)piperidin-4-yl)-*N*-(2-fluorophenyl)propionamide (Other name: 2'-fluoro-*o*-fluorofentanyl);

(1-2-2) *N*-(2-Methylphenyl)-*N*-(1-phenethylpiperidin-4-yl)acetamide (Other name: *o*-methyl acetylfentanyl);

(1-2-3) *N*-(1-Phenethylpiperidin-4-yl)-*N*,3-diphenylpropanamide (Other names:  $\beta'$ -phenyl fentanyl; hydrocinnamoyl fentanyl); and,

(1-2-4) *N*-(1-Phenethylpiperidin-4-yl)-*N*-phenylthiophene-2-carboxamide (Other name: thiofuranyl fentanyl).

(2) 2-(2-(4-Butoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)-*N,N*-diethylethan-1-amine (Other name: butonitazene);

(3) 2-(2-(4-Ethoxybenzyl)-1*H*-benzimidazol-1-yl)-*N,N*-diethylethan-1-amine (Other names: etodesnitazene; etazene);

(4) *N,N*-Diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1*H*-benzimidazol-1-yl)ethan-1-amine (Other name: flunitazene);

(5) *N,N*-Diethyl-2-(2-(4-methoxybenzyl)-1*H*-benzimidazol-1-yl)ethan-1-amine (Other name: metodesnitazene);

~~\*(6) *N,N*-Diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)ethan-1-amine (Other name: metonitazene);~~

(6) 2-(4-Ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1*H*-benzimidazole (Other names: *N*-pyrrolidino etonitazene; etonitazepyne);

(7) *N,N*-Diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1*H*-benzimidazol-1-yl)ethan-1-amine (Other name: protonitazene);

\*(8) 4-(2-chlorophenyl)-2-ethyl-9-methyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*σ*][1,4]diazepine (Other name: etizolam);

\*(9) 8-chloro-6-(2-fluorophenyl)-1-methyl-4*H*-benzo[*f*][1,2,4]triazolo[4,3-*σ*][1,4]diazepine (Other name: flualprazolam);

\*(10) 6-(2-chlorophenyl)-1-methyl-8-nitro-4*H*-benzo[*f*][1,2,4]triazolo[4,3-*σ*][1,4]diazepine (Other name: clonazolam);

\*(11) 8-bromo-6-(2-fluorophenyl)-1-methyl-4*H*-benzo[*f*][1,2,4]triazolo[4,3-*σ*][1,4]diazepine (Other names: 8-bromo-6-(2-fluorophenyl)-1-methyl-4*H*-[1,2,4]triazolo[4,3-*σ*][1,4]benzodiazepine and flubromazolam); and,

\*(12) 7-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2*H*-benzo[*e*][1,4]diazepin-2-one (Other name: diclazepam).

### **-Schedule III anabolic steroids and hormones**

\*Anabolic steroids. Unless specifically excepted or unless listed in another schedule, any substance meeting the definition of anabolic steroid as set forth in 21 CFR §1300.01, including any material, compound, mixture or preparation containing any quantity of the following substances, including its salts, esters and ethers:

(1) 5α-androstan-3,17-dione;

\*(2) 5α-androstan-3,6,17-trione;

(3) 1-androstenediol (3β,17β-dihydroxy-5α-androst-1-ene);

(4) 1-androstenediol (3α,17β-dihydroxy-5α-androst-1-ene);

(5) 4-androstenediol (3β,17β-dihydroxy-androst-4-ene);

(6) 5-androstenediol (3β,17β-dihydroxy-androst-5-ene);

(7) 1-androstenedione (5α-androst-1-en-3,17-dione);

(8) 4-androstenedione (androst-4-en-3,17-dione);

(9) 5-androstenedione (androst-5-en-3,17-dione);

(10) bolasterone (7α,17α-dimethyl-17β-hydroxyandrost-4-en-3-one);

(11) boldenone (17β-hydroxyandrost-1,4-diene-3-one);

- (12) boldione (androsta-1,4-diene-3,17-dione);
- \*(13) 6-bromo-androsta-1,4-diene-3,17-dione;
- \*(14) 6-bromo-androstan-3,17-dione;
- (15) calusterone (7 $\beta$ ,17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyandrost-4-en-3-one);
- \*(16) 4-chloro-17 $\alpha$ -methyl-androsta-1,4-diene-3,17 $\beta$ -diol;
- \*(17) 4-chloro-17 $\alpha$ -methyl-androst-4-ene-3 $\beta$ ,17 $\beta$ -diol;
- \*(18) 4-chloro-17 $\alpha$ -methyl-17 $\beta$ -hydroxy-androst-4-en-3-one;
- \*(19) 4-chloro-17 $\alpha$ -methyl-17 $\beta$ -hydroxy-androst-4-ene-3,11-dione;
- (20) clostebol (4-chloro-17 $\beta$ -hydroxyandrost-4-en-3-one);
- (21) dehydrochloromethyltestosterone (4-chloro-17 $\beta$ -hydroxy-17 $\alpha$ -methyl-androst-1,4-dien-3-one);
- (22) desoxymethyltestosterone (17 $\alpha$ -methyl-5 $\alpha$ -androst-2-en-17 $\beta$ -ol) (Other name: madol);
- (23) 4-dihydrotestosterone (17 $\beta$ -hydroxy-androstan-3-one);
- (24)  $\Delta$ 1-dihydrotestosterone (17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-3-one) (Other name: 1-testosterone);
- (25) 3 $\beta$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstane;
- (26) 3 $\alpha$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstane;
- \*(27) 2 $\alpha$ ,17 $\alpha$ -dimethyl-17 $\beta$ -hydroxy-5 $\beta$ -androstane-3-one;
- (28) drostanolone (17 $\beta$ -hydroxy-2 $\alpha$ -methyl-5 $\alpha$ -androstane-3-one);
- \*(29) 2 $\alpha$ ,3 $\alpha$ -epithio-17 $\alpha$ -methyl-5 $\alpha$ -androstane-17 $\beta$ -ol;
- \*(30) estra-4,9,11-triene-3,17-dione;
- (31) 13 $\beta$ -ethyl-17 $\beta$ -hydroxygon-4-en-3-one;
- (32) ethylestrenol (17 $\alpha$ -ethyl-17 $\beta$ -hydroxyestr-4-ene);
- (33) fluoxymesterone (9-fluoro-17 $\alpha$ -methyl-11 $\beta$ ,17 $\beta$ -dihydroxyandrost-4-en-3-one);
- (34) formebolone (2-formyl-17 $\alpha$ -methyl-11 $\alpha$ ,17 $\beta$ -dihydroxyandrost-1,4-dien-3-one);
- (35) furazabol (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrostan[2,3-c]furazan);
- \*(36) [3,2-c]furazan-5 $\alpha$ -androstane-17 $\beta$ -ol;
- \*(37) 18 $\alpha$ -homo-3-hydroxy-estra-2,5(10)-dien-17-one;
- (38) 4-hydroxy-19-nortestosterone (4,17 $\beta$ -dihydroxy-estr-4-en-3-one);
- \*(39) 4-hydroxy-androst-4-ene-3,17-dione;
- \*(40) 17 $\beta$ -hydroxy-androstano[2,3-d]isoxazole;
- \*(41) 17 $\beta$ -hydroxy-androstano[3,2-c]isoxazole;
- \*(42) 3 $\beta$ -hydroxy-estra-4,9,11-trien-17-one;
- (43) 4-hydroxytestosterone (4,17 $\beta$ -dihydroxy-androst-4-en-3-one);
- (44) mestanolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-5 $\alpha$ -androstane-3-one);
- (45) mesterolone (1 $\alpha$ -methyl-17 $\beta$ -hydroxy-5 $\alpha$ -androstane-3-one);
- (46) methandienone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrost-1,4-dien-3-one);
- (47) methandriol (17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-5-ene);



- (48) methasterone (2 $\alpha$ ,17 $\alpha$ -dimethyl-5 $\alpha$ -androstan-17 $\beta$ -ol-3-one or 2 $\alpha$ ,17 $\alpha$ -dimethyl-17 $\beta$ -hydroxy-5 $\alpha$ -androstan-3-one);
- (49) methenolone (1-methyl-17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-3-one);
- \*(50) 17 $\alpha$ -methyl-androsta-1,4-diene-3,17 $\beta$ -diol;
- \*(51) 17 $\alpha$ -methyl-5 $\alpha$ -androstan-17 $\beta$ -ol;
- \*(52) 17 $\alpha$ -methyl-androstan-3-hydroxyimine-17 $\beta$ -ol;
- \*(53) 6 $\alpha$ -methyl-androst-4-ene-3,17-dione;
- \*(54) 17 $\alpha$ -methyl-androst-2-ene-3,17 $\beta$ -diol;
- (55) 17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstan-3-one;
- (56) 17 $\alpha$ -methyl-3 $\alpha$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstan-3-one;
- (57) 17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-4-ene-3-one;
- (58) 17 $\alpha$ -methyl-4-hydroxynandrolone (17 $\alpha$ -methyl-4-hydroxy-17 $\beta$ -hydroxyestr-4-en-3-one);
- (59) methyldienolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-4,9(10)-dien-3-one);
- (60) 17 $\alpha$ -methyl- $\Delta$ 1-dihydrotestosterone (17 $\beta$ -hydroxy-17 $\alpha$ -methyl-5 $\alpha$ -androst-1-en-3-one) (Other name: 17- $\alpha$ -methyl-1-testosterone);
- (61) methyltestosterone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrost-4-en-3-one);
- (62) methyltrienolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-4,9,11-trien-3-one);
- (63) mibolerone (7 $\alpha$ ,17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyestr-4-en-3-one);
- (64) nandrolone (17 $\beta$ -hydroxyestr-4-en-3-one);
- (65) 19-nor-4-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxyestr-4-ene);
- (66) 19-nor-4-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxyestr-4-ene);
- (67) 19-nor-5-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxyestr-5-ene);
- (68) 19-nor-5-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxyestr-5-ene);
- (69) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);
- (70) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
- (71) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
- (72) norbolethone (13 $\beta$ ,17 $\alpha$ -diethyl-17 $\beta$ -hydroxygon-4-en-3-one);
- (73) norclostebol (4-chloro-17 $\beta$ -hydroxyestr-4-en-3-one);
- (74) norethandrolone (17 $\alpha$ -ethyl-17 $\beta$ -hydroxyestr-4-en-3-one);
- (75) normethandrolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestr-4-en-3-one);
- (76) oxandrolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-2-oxa-5 $\alpha$ -androstan-3-one);
- (77) oxymesterone (17 $\alpha$ -methyl-4,17 $\beta$ -dihydroxyandrost-4-en-3-one);
- (78) oxymetholone (17 $\alpha$ -methyl-2-hydroxymethylene-17 $\beta$ -hydroxy-5 $\alpha$ -androstan-3-one);
- (79) prostanazol (17 $\beta$ -hydroxy-5 $\alpha$ -androstan-3-ylpyrazole or [3,2-c]pyrazole-5 $\alpha$ -androstan-17 $\beta$ -ol);
- \*(80) [3,2-c]pyrazole-androst-4-en-17 $\beta$ -ol;
- (81) stanozolol (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-5 $\alpha$ -androst-2-eno[3,2-c]-pyrazole);
- (82) stenbolone (17 $\beta$ -hydroxy-2-methyl-5 $\alpha$ -androst-1-en-3-one);
- (83) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);

- (84) testosterone (17 $\beta$ -hydroxyandrost-4-en-3-one);
- (85) tetrahydrogestrinone (13 $\beta$ ,17 $\alpha$ -diethyl-17 $\beta$ -hydroxygon-4,9,11-trien-3-one);
- and
- (86) trenbolone (17 $\beta$ -hydroxyestr-4,9,11-trien-3-one).

Changes are marked by an asterisk(\*)

TRD-202400377  
Cynthia Hernandez  
General Counsel  
Department of State Health Services  
Filed: January 31, 2024



**Texas Higher Education Coordinating Board**

Meeting of Negotiated Rulemaking Committee on 100-Mile Non-State Resident Tuition Waiver

Date of Meeting: February 21, 2024

Start Time of Meeting: 9:30 a.m.

Additional Information Obtained From: Laurie Frederick, Convener, Laurie.Frederick@highered.texas.gov

Agenda:

1. Introductions
2. Brief Overview of the Negotiated Rulemaking Process: What it is, What it's not
3. Brief Overview of Roles and Responsibilities
  - a) Role of Facilitator
  - b) Role of Sponsor Agency
  - c) Role of Committee Members
4. Consideration and Possible Action to Approve Facilitator
5. Procedural Issues
  - a) Consideration and Possible Action to Approve Ground Rules
  - b) Consideration and Possible Action to Approve Definition of Consensus
6. Discussion of Draft Rule Language on 100-Mile Non-State Resident Tuition Waiver
7. Consideration and Possible Action to Approve Proposed Rule Language on 100-Mile Non-State Resident Tuition Waiver

Individuals who may require auxiliary aids or services for this meeting should contact Glenn Tramel, ADA Coordinator, at (512) 427-6193 at least five days before the meeting so that appropriate arrangements can be made.

TRD-202400358  
Nichole Bunker-Henderson  
General Counsel  
Texas Higher Education Coordinating Board  
Filed: January 31, 2024



Meeting of Negotiated Rulemaking Committee on Nursing Scholarship Program

Date of Meeting: February 26, 2024

Start Time of Meeting: 9:30 a.m.

Additional Information Obtained From: Laurie Frederick, Convener, Laurie.Frederick@highered.texas.gov

Agenda:

1. Introductions
2. Brief Overview of the Negotiated Rulemaking Process: What it is, What it's not
3. Brief Overview of Roles and Responsibilities
  - a) Role of Facilitator
  - b) Role of Sponsor Agency
  - c) Role of Committee Members
4. Consideration and Possible Action to Approve Facilitator
5. Procedural Issues
  - a) Consideration and Possible Action to Approve Ground Rules
  - b) Consideration and Possible Action to Approve Definition of Consensus
6. Discussion of Draft Rule Language on Nursing Scholarship Program
7. Consideration and Possible Action to Approve Proposed Rule Language on Nursing Scholarship Program

Individuals who may require auxiliary aids or services for this meeting should contact Glenn Tramel, ADA Coordinator, at (512) 427-6193 at least five days before the meeting so that appropriate arrangements can be made.

TRD-202400359  
Nichole Bunker-Henderson  
General Counsel  
Texas Higher Education Coordinating Board  
Filed: January 31, 2024



Meeting of Negotiated Rulemaking Committee on Professional Nursing Shortage Reduction Program

Date of Meeting: February 20, 2024

Start Time of Meeting: 9:30 a.m.

Additional Information Obtained From: Laurie Frederick, Convener, Laurie.Frederick@highered.texas.gov

Agenda: